Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Placebo-Controlled, Randomized, Blinded Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ARD-101 in Adults With Obesity

NCT05121441 is registered in ClinicalTrials.gov with Aardvark Therapeutics, Inc. as lead sponsor.

NCT NCT05121441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05121441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Placebo-Controlled, Randomized, Blinded Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ARD-101 in Adults With Obesity
Lead sponsor
Aardvark Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2021
Completion date
November 9, 2022
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity